Sapio Life focuses its expansion in Spain with new services and opens up to acquisitions

The Sapio Group’s healthcare division is focusing its international expansion in Spain with the launch of new services. The company specializing in respiratory therapies will allocate a total of $35.6 million (€30 million) to the Spanish market, the largest investment after Italy, without taking into account possible acquisitions. 

The company entered the Spanish market in October 2019 after Grupo Sapio bought Contse. Sapio Life has identified Spain as a priority market among its internationalization outside Italy, which also focuses on France, Germany, Slovenia, and Turkey. The Sapio Group’s healthcare division markets respiratory home therapies in the Spanish market, but is considering launching new services that it already offers in other countries. 

Sapio Life plans to launch in Spain “infusion therapies, nutrition, dialysis and long-term home health care,” said Francesca Paludetti, managing director of Sapio Life. 

Read more about Sapio Group’s healthcare division and find other important business news with the Born2Invest mobile app.

Sapio Life operates in Italy, Spain, France, Germany, Slovenia and Turkey 

Sapio Group also owns laboratory analysis and cryogenetics companies that offer diagnostic tests for Covid-19, hyperbaric chambers and other health care aids, in addition to owning clinics in Italy and Germany. 

The company seeks to increase both the number and type of therapies provided in Spain. The expansion plan, in addition to organic growth, also includes possible deals and acquisitions. “We are interested in investing in respiratory therapies if there is an opportunity for acquisitions, we are looking at similar businesses that accompany what we are already doing to expand into other typologies,” Paludetti assures. The group is open to acquisitions, although without time targets. 

The company specializing in home therapies is also looking to grow through public tenders, a system that differs from the other markets where Grupo Sapio’s healthcare division operates, which combine public tenders with accreditation. This process consists of the physician choosing the therapy and provider that should deliver its services to the patient. The Italian market used to have the same procedure as the one currently in place in Spain, but now combines public tenders with accreditation. Paludetti explains that, although the system of public tenders hinders growth, “the company knows the process well and has the experience of Italy”.  

Sapio Life invoiced $5.35 million (€4.5 million) in Spain in 2020 and aims for twenty million in five years 

Sapio Life is awaiting the resolution of a public tender in Spain and Paludetti also points out that there are several processes that have been delayed by the pandemic. Sapio Group’s healthcare division had a turnover of $5.35 million (€4.5 million) in 2020 in the Spanish market and expects to reach $23.76 million (€20 million) in five years. The company specializing in respiratory therapies performs 20,000 therapies in Spain after being awarded the contract for home respiratory treatments in the province of Huelva for the Andalusian Health Service for the past five years and for the health areas of Cartagena and Mar Menor in Murcia in 2019. In total, the company offers its services to more than 150,000 patients in Europe.

Sapio Life has a plant in Spain in San Sebastián de los Reyes (Madrid) and forty employees, after expanding it by 20% in the last year. Sapio Group, which also produces technical and industrial gases, recorded a turnover of $760 million (€640 million) in 2020. The company has 2,200 employees and is owned by two Italian families and Air Products, which controls 49% of the shareholding.

__

(Featured image by AlexFedini via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.